News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Cumulatively, almost 75% of the health centres in the country have been electrified with a cumulative solar capacity of 3.5 MW
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Funds raised will be used to develop technology and foster healthcare partnerships
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Subscribe To Our Newsletter & Stay Updated
